Abstract

Animal poisons and venoms are comprised of different classes of molecules displaying wide-ranging pharmacological activities. This review aims to provide an in-depth view of toxin-based compounds from terrestrial and marine organisms used as diagnostic tools, experimental molecules to validate postulated therapeutic targets, drug libraries, prototypes for the design of drugs, cosmeceuticals, and therapeutic agents. However, making these molecules applicable requires extensive preclinical trials, with some applications also demanding clinical trials, in order to validate their molecular target, mechanism of action, effective dose, potential adverse effects, as well as other fundamental parameters. Here we go through the pitfalls for a toxin-based potential therapeutic drug to become eligible for clinical trials and marketing. The manuscript also presents an overview of the current picture for several molecules from different animal venoms and poisons (such as those from amphibians, cone snails, hymenopterans, scorpions, sea anemones, snakes, spiders, tetraodontiformes, bats, and shrews) that have been used in clinical trials. Advances and perspectives on the therapeutic potential of molecules from other underexploited animals, such as caterpillars and ticks, are also reported. The challenges faced during the lengthy and costly preclinical and clinical studies and how to overcome these hindrances are also discussed for that drug candidates going to the bedside. It covers most of the drugs developed using toxins, the molecules that have failed and those that are currently in clinical trials. The article presents a detailed overview of toxins that have been used as therapeutic agents, including their discovery, formulation, dosage, indications, main adverse effects, and pregnancy and breastfeeding prescription warnings. Toxins in diagnosis, as well as cosmeceuticals and atypical therapies (bee venom and leech therapies) are also reported. The level of cumulative and detailed information provided in this review may help pharmacists, physicians, biotechnologists, pharmacologists, and scientists interested in toxinology, drug discovery, and development of toxin-based products.

Highlights

  • Animal poisons and venoms are rich sources of proteins, peptides, neurotransmitters, among other compounds

  • Since the toxin targets are related to biological functions, with many of them playing important roles in human diseases, several venom components were used in the design of new therapeutic agents

  • The small amount obtained from different poisonous and venomous animals, together with the nature of the venom/ poison allied with the difficulty in isolating specific toxins, are the main limitations faced during basic research

Read more

Summary

INTRODUCTION

Animal poisons and venoms are rich sources of proteins, peptides, neurotransmitters, among other compounds. Since the toxin targets are related to biological functions, with many of them playing important roles in human diseases, several venom components were used in the design of new therapeutic agents. They were employed as cosmeceuticals, diagnostic tools, and experimental molecules to validate postulated therapeutic targets, improving several drug libraries (Ghosh et al, 2019; Utkin et al, 2019). This review aims to highlight the key successes and some examples of the obstacles and challenges faced when developing toxin-based drugs It covers toxins from poisonous and venomous animals, drugs that target diverse pathological conditions, the molecules that have failed, and those that are currently in clinical trials. Perspectives on the research and development of a wide range of toxins from several underexploited animal poisons and venoms are discussed

ACHIEVEMENTS WITH ANIMAL TOXINBASED MOLECULES
Approved Drugs
Whole venom
Pain associated with osteoarthritis and multiple sclerosis
Microvascular thrombosis
Anticoagulant in percutaneous coronary intervention
European medicinal leech
Synthetic Synthetic
Leeches drain blood from tissue
Acute coronary syndrome
Diagnostic Tools
Venom Therapies
Challenges Regarding Basic Research
Challenges Regarding Preclinical Evaluation
Challenges Regarding Clinical Trials
LEARNING FROM DISCONTINUED TOXINBASED DRUGS
PROMISING ANIMAL TOXINS IN PRECLINICAL STAGE AND CLINICAL TRIALS
Intractable epilepsy
Naja naja atra
Detoxified or chemically modified
Prevention of venous
Phase I
Cone Snails
Sea Anemones
Other Animals
CONCLUSION
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call